Viking Therapeutics stock jumped after Madrigal Pharmaceuticals posted trial results for their new NASHf treatment. A similar parallel move occurred in 2018. Viking could potentially be a buyer for Madrigal’s new drug. VKTX has long been a promising stock, and they still persist. EPS, technically, is negative, but value is growing (so this could change […]